Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In total, 11 FDR-significant clinical chemistry biomarkers were carried forward for joint modelling with SCORE2 (see Supplementary data online, Table S4): cystatin-C, CRP, alkaline phosphatase (ALP), albumin, gamma glutamyltransferase (GGT), lipoprotein(a) [Lp(a)], aspartate aminotransferase (AST), glycated haemoglobin (HbA1c), urate, vitamin D, and apolipoprotein A1 (ApoA1).

Source: Addition of multivariable biomarker models to SCORE2. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were also excluded if they did not consent to electronic health record linkage, had incomplete data on SCORE2 risk factors, were ineligible for PRS assessment, or failed NMR biomarker quality control.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction

Study design awaiting verification · European Heart Journal · 2026

Original publication title

Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction

Scott C Ritchie; Xilin Jiang; Lisa Pennells; Yu Xu; Claire Coffey; Yang Liu; Joel T Gibson; Praveen Surendran; Savita Karthikeyan; Samuel A Lambert; John Danesh; Adam S Butterworth; Angela Wood; Stephen Kaptoge; Emanuele Di Angelantonio; Michael Inouye

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Combining NMR metabolomic, polygenic, and clinical biomarkers with SCORE2 enhanced prediction of first-onset CVD and could have substantial population health benefit if applied at scale.

An extract from the source publication. Read it in context.

At a glance

Abstract: Background and Aims

Clinical biomarkers, nuclear magnetic resonance (NMR) metabolomics biomarker scores, and polygenic risk scores (PRS) have shown promise for improving cardiovascular disease (CVD) prediction but have not yet been evaluated in the context of current prediction models (SCORE2) and ESC recommendations for 10-year prediction of fatal and non-fatal CVD.

Source: Background and Aims

Abstract: What methods does the paper describe?

NMR metabolomic biomarker scores were constructed and compared to clinical biomarkers, PRS and SCORE2 in 297 463 UK Biobank participants (8919 incident CVD cases) aged 40 to 69 without previous CVD, diabetes, or lipid-lowering treatment. Improvement in risk discrimination when added to SCORE2 was assessed using Harrel’s C-index. Improvement in risk stratification following ESC guideline risk thresholds was assessed using categorical net reclassification. Population modelling was subsequently applied to estimate the impact on CVD prevention if applied at scale.

Source: Methods

Abstract: Results

Risk discrimination provided by SCORE2 (C-index: 0.719) improved when 11 clinical biomarkers (ΔC-index: 0.014 [0.012 to 0.015]), NMR metabolomic biomarker scores (ΔC-index: 0.010 [0.009 to 0.012]) and PRSs (ΔC-index 0.009; [0.008 to 0.011]) were added individually. The combination of 11 clinical biomarkers, NMR metabolomic biomarker scores, and PRSs yielded the largest improvement risk discrimination, with ΔC-index 0.024 (0.022 to 0.027). Concomitant improvements in risk stratification were observed in categorical net reclassification index, with net case reclassification of 16.66% (15.50%: 17.81%). Modelling suggested that addition of these biomarkers to SCORE2 for targeted risk reclassification would increase the number of CVD events prevented per 100 000 screened from 229 to 413 (ΔCVDprevented: 184 [174 to 194]) while essentially maintaining the number of statins prescribed per CVD event prevented.

Source: Results

Abstract: Conclusions

Combining NMR metabolomic, polygenic, and clinical biomarkers with SCORE2 enhanced prediction of first-onset CVD and could have substantial population health benefit if applied at scale.

Source: Conclusions
Authors’ abstract

Abstract

Background and Aims

Clinical biomarkers, nuclear magnetic resonance (NMR) metabolomics biomarker scores, and polygenic risk scores (PRS) have shown promise for improving cardiovascular disease (CVD) prediction but have not yet been evaluated in the context of current prediction models (SCORE2) and ESC recommendations for 10-year prediction of fatal and non-fatal CVD.

Methods

NMR metabolomic biomarker scores were constructed and compared to clinical biomarkers, PRS and SCORE2 in 297 463 UK Biobank participants (8919 incident CVD cases) aged 40 to 69 without previous CVD, diabetes, or lipid-lowering treatment. Improvement in risk discrimination when added to SCORE2 was assessed using Harrel’s C-index. Improvement in risk stratification following ESC guideline risk thresholds was assessed using categorical net reclassification. Population modelling was subsequently applied to estimate the impact on CVD prevention if applied at scale.

Results

Risk discrimination provided by SCORE2 (C-index: 0.719) improved when 11 clinical biomarkers (ΔC-index: 0.014 [0.012 to 0.015]), NMR metabolomic biomarker scores (ΔC-index: 0.010 [0.009 to 0.012]) and PRSs (ΔC-index 0.009; [0.008 to 0.011]) were added individually. The combination of 11 clinical biomarkers, NMR metabolomic biomarker scores, and PRSs yielded the largest improvement risk discrimination, with ΔC-index 0.024 (0.022 to 0.027). Concomitant improvements in risk stratification were observed in categorical net reclassification index, with net case reclassification of 16.66% (15.50%: 17.81%). Modelling suggested that addition of these biomarkers to SCORE2 for targeted risk reclassification would increase the number of CVD events prevented per 100 000 screened from 229 to 413 (ΔCVDprevented: 184 [174 to 194]) while essentially maintaining the number of statins prescribed per CVD event prevented.

Conclusions

Combining NMR metabolomic, polygenic, and clinical biomarkers with SCORE2 enhanced prediction of first-onset CVD and could have substantial population health benefit if applied at scale.

Publication and source details

Original title: Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction

Scott C Ritchie; Xilin Jiang; Lisa Pennells; Yu Xu; Claire Coffey; Yang Liu; Joel T Gibson; Praveen Surendran; Savita Karthikeyan; Samuel A Lambert; John Danesh; Adam S Butterworth; Angela Wood; Stephen Kaptoge; Emanuele Di Angelantonio; Michael Inouye

European Heart Journal · 2026

Corresponding authors. Email: sr827@medschl.cam.ac.uk (S.C.R), mi336@cam.ac.uk (M.I.)© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Engineering and Physical Sciences Research Council10.13039/501100000266 EP/P020259/1 Science and Technology Facilities Council10.13039/501100000271

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:09:12.443920+00:00

DOI: 10.1093/eurheartj/ehaf947 · PMC13079997